Survival Analysis with 5 years of Follow-Up in a Phase III Study of Ipilimumab and Dacarbazine in Metastatic Melanoma — ASN Events
  1. Schedule
  2. Posters - Clinical research
  3. Survival Analysis with 5 years of Follow-Up in a Phase III Study of Ipilimumab and Dacarbazine in Metastatic Melanoma

Survival Analysis with 5 years of Follow-Up in a Phase III Study of Ipilimumab and Dacarbazine in Metastatic Melanoma (#169)

Michele Maio 1 , Igor Bondarenko 2 , Caroline Robert 3 , Luc Thomas 4 , Claus Garbe 5 , Alessandro Testori 6 , Haolan Lu 7 , Kevin Chin 7 , Jedd Wolchok 8
  1. University Hospital of Siena, Siena, Italy
  2. Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine
  3. Institute Gustave Roussy, Villejuif, France
  4. Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite, France
  5. University Medical Centre, Tuebingen, Germany
  6. Instituto Europeo di Oncologia, Milan, Italy
  7. Bristol-Myers Squibb, Wallingford, CT, United States
  8. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Publish consent withheld